BMS rises on earnings, promise of cost containment

Along with reporting 3Q16 earnings that beat estimates and raising full-year guidance, Bristol-Myers Squibb Co. (NYSE:BMY) on Thursday announced it would keep non-GAAP operating expenses "roughly flat" in 2016-20, even as it increases R&D spending in priority

Read the full 374 word article

User Sign In